This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
Home
Products
Trurapi®▼ (insulin aspart 100 units/mL)
Trurapi Hero Pen

Trurapi®

insulin aspart 100 units/mL

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

The first rapid acting insulin biosimilar of NovoRapid® approved in the UK and EU.1

Profile

30% lower NHS list price vs. NovoRapid® pre-filled pens and cartridges and 15% lower NHS list price vs. NovoRapid® vials.2

1:1 initial unit dosing - available in the SoloStar pen, cartridges and vials1*

*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1

Similar PK/PD profile (T1DM),efficacy, safety and tolerability (T1DM and T2DM).3-4

1/3

30% lower NHS list price vs. NovoRapid® pre-filled pens and cartridges and 15% lower NHS list price vs. NovoRapid® vials.2

1:1 initial unit dosing - available in the SoloStar pen, cartridges and vials1*

*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1

Similar PK/PD profile (T1DM),efficacy, safety and tolerability (T1DM and T2DM).3-4

Diabetes Stories

Watch peer-to-peer videos of payors and healthcare professionals sharing best practices of adopting a rapid acting insulin biosimilar. Some of these videos are related to HCPs sharing their experiences with a different rapid acting insulin biosimilar.

Nichola Hughes – Hospital Diabetes Specialist Nurse

Length: 04:10

In this video you can learn from Nichola how to overcome possible resistance from patients, the steps she took to initiate/switch a patient to a rapid-acting insulin biosimilar and how the patient experience has been with this biosimilar.

Paula Johnston - Lead Inpatient Diabetes Specialist Nurse

Length: 02:22

In this video you can learn from Paula Johnston how she achieved a positive patient experience with this biosimilar and how she carried out an opportunistic switch of existing patients, when appropriate.

Dr Duncan Browne - Consultant Endocrinologist

Length: 03:32

In this video you can learn why Duncan Browne decided to prescribe a rapid acting insulin biosimilar, how he aligned internally the local service to drive the adoption of this biosimilar in his local region and find out how the patient experience has been with this biosimilar.

Dr Saqib Mahmud - Primary Care Consultant

Length: 02:55

In this video you can learn from Dr. Saqib Mahmud why he decided to prescribe a rapid acting insulin biosimilar and get practical recommendations when switching patients to a rapid acting insulin biosimilar.

Amanda Veall - Diabetes Specialist Nurse

Length: 04:16

In this video you can learn why Amanda Veall decided to prescribe a rapid acting insulin biosimilar, how she collaborated with clinical teams to drive the adoption of this biosimilar in her local region and find out how the patient experience has been with this biosimilar.

Marcus Jones - Formulary Pharmacist

Length: 03:43

In this video you can learn how Marcus Jones accelerated the adoption of a rapid acting biosimilar insulin in his local region and how he collaborated with clinical teams to make a positive start and switch.

Start and Switch

Watch and download resources to support your rapid acting insulin adoption.

Sohail Akhtar - 19.02.24 - 16:56

Print and distribute this card for your patient to enable an easy access to support materials.

Trurapi Leaflet

This leaflet gives you an overview of the clinical evidence, price comparison of Trurapi® versus NovoRapid® and information on 1:1 dosing and the different presentations available.

Formulary FAQ

This FAQ document provides factual and technical information about Trurapi® to support you with relevant documentation for local formulary applications.

Trurapi Poster

Pharmacists and other Healthcare Professionals can print this poster and put it in drug fridges to provide information about Trurapi.

Slide Deck

This slide deck can be used to support Health Care Professional training on Trurapi®. It gives an overview of the clinical evidence, information on 1:1 dosing, the different presentations available and price comparison of Trurapi® versus NovoRapid®.

Retailer Query

This document supports medicines management teams and clinical customers to deal with retailer queries on how to purchase Trurapi®️.

What is a Biosimilar Medicine?

Length: 07:04

Get the answer in this video by Nurse Consultant in Diabetes, Grace Vanterpool or read the video summary.

Diabetes Stories

Length: 04:02

You can watch briefly how a payor, an endocrinologist and a diabetes specialist nurse implemented a rapid acting biosimilar insulin in their local region and how they collaborated with clinical teams and patients to make a positive start and switch.

Get in touch with the Diabetes Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023

MAT-XU-2205461 (v9.0)  Date of Preparation: February 2024